Willemijn Hobo

3.0k citations

50 papers · 2.2k indexed · h-index 26

Immunology top 2%
Oncology top 2%
Molecular Biology
Hematology top 5%
Radiology, Nuclear Medicine and Imaging top 10%

Co-authors: Harry Dolstra Nicolaas Schaap Robbert van der Voort Frans Maas Anniek B. van der Waart Joop H. Jansen Hanny Fredrix J.H. Frederik Falkenburg
Topics: Immune Cell Function and Interaction (29 papers)CAR-T cell therapy research (23 papers)Immunotherapy and Immune Responses (21 papers)
Cited by: Immunology Oncology Hematology
Journals: Nature Communications Blood The Journal of Immunology
Partner nations: Netherlands United States Germany

In The Last Decade

Willemijn Hobo

49 papers receiving 2.1k citations

Peers

Countries citing papers authored by Willemijn Hobo

Since Specialization

Citations

This map shows the geographic impact of Willemijn Hobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willemijn Hobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willemijn Hobo more than expected).

Fields of papers citing papers by Willemijn Hobo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willemijn Hobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willemijn Hobo. The network helps show where Willemijn Hobo may publish in the future.

Co-authorship network of co-authors of Willemijn Hobo

This figure shows the co-authorship network connecting the top 25 collaborators of Willemijn Hobo. A scholar is included among the top collaborators of Willemijn Hobo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willemijn Hobo. Willemijn Hobo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull mice 2025 ·Cellular and Molecular Life Sciences ·(unknown),(unknown),(unknown),(unknown),Vanessa Rodríguez‐Fanjul,Willemijn Hobo,Anna L. de Goede,Suzanne van Dorp,Joop H. Jansen,Anniek B. van der Waart,Paul K.J.D. de Jonge,Harry Dolstra	2
2	Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial 2025 ·Gynecologic Oncology ·Janneke S. Hoogstad‐van Evert,Paul K.J.D. de Jonge,Petra L.M. Zusterzeel,Willemijn Hobo,Anniek B. van der Waart,Hanny Fredrix,(unknown),(unknown),(unknown),(unknown),(unknown),Vanessa Rodríguez‐Fanjul,Anna L. de Goede,Bert A. van der Reijden,Arnold van der Meer,Nicolaas Schaap,Ruud L.M. Bekkers,Joop H. Jansen,Nelleke Ottevanger,Harry Dolstra	1
3	Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo 2023 ·Cellular and Molecular Life Sciences ·(unknown),(unknown),Jolanda Brummelman,(unknown),(unknown),(unknown),Dorette S. van Ingen Schenau,Mirjam H.M. Heemskerk,Marieke Griffioen,Michel G.D. Kester,Nicolaas Schaap,Joop H. Jansen,Anniek B. van der Waart,Harry Dolstra,Willemijn Hobo	2
4	Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity 2023 ·Cytotherapy ·(unknown),(unknown),(unknown),Anniek B. van der Waart,Willemijn Hobo,Jianming Wu,Nicole M. A. Blijlevens,Joop H. Jansen,Bruce Walcheck,Nicolaas Schaap,Paul K.J.D. de Jonge,Harry Dolstra	6
5	Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses 2021 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),Soley Thordardottir,(unknown),(unknown),Anniek B. van der Waart,J.H. Frederik Falkenburg,Michel G.D. Kester,Iris de Rink,Mirjam H.M. Heemskerk,Jannie Borst,Nicolaas Schaap,Joop H. Jansen,Yanling Xiao,Harry Dolstra,Willemijn Hobo	16
6	CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^null mice 2021 ·OncoImmunology ·(unknown),Paul K.J.D. de Jonge,Anniek B. van der Waart,(unknown),(unknown),Jolanda Brummelman,(unknown),(unknown),(unknown),Nicolaas Schaap,Janneke S. Hoogstad‐van Evert,Petronella B. Ottevanger,Joop H. Jansen,Willemijn Hobo,Harry Dolstra	14
7	TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer 2020 ·OncoImmunology ·(unknown),Janneke S. Hoogstad‐van Evert,(unknown),(unknown),(unknown),Alan J. Korman,Paul K.J.D. de Jonge,Jeannette Cany,Rob Woestenenk,Nicolaas Schaap,Leon F.A.G. Massuger,Joop H. Jansen,Willemijn Hobo,Harry Dolstra	54
8	Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells 2020 ·Cancer Immunology Immunotherapy ·(unknown),Willemijn Hobo,(unknown),(unknown),Nicolaas Schaap,Joop H. Jansen,Anniek B. van der Waart,Harry Dolstra	3
9	IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells 2020 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),Karolin Guldevall,(unknown),Paul K.J.D. de Jonge,Janneke S. Hoogstad‐van Evert,Anniek B. van der Waart,Jeannette Cany,Jeffrey T. Safrit,(unknown),Esther Wagena,Peter Friedl,Björn Önfelt,Leon F.A.G. Massuger,Nicolaas Schaap,Joop H. Jansen,Willemijn Hobo,Harry Dolstra	33
10	PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity 2020 ·Bone Marrow Transplantation ·(unknown),(unknown),(unknown),Anniek B. van der Waart,Diana Campillo-Davó,(unknown),(unknown),Hanny Fredrix,Rob Woestenenk,Loreto Parga‐Vidal,Joop H. Jansen,Nicolaas Schaap,Eva Lion,Harry Dolstra,Willemijn Hobo	15
11	Comprehensive Phenotyping of T Cells Using Flow Cytometry 2019 ·Cytometry Part A ·(unknown),Willemijn Hobo,Rob Woestenenk,Frank Preijers,Harry Dolstra,Anniek B. van der Waart	137
12	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer 2018 ·Cancer Immunology Research ·Sandra Heskamp,(unknown),Janneke D.M. Molkenboer‐Kuenen,(unknown),Soley Thordardottir,Jeannette Cany,Daniel Olive,Johan Bussink,Otto C. Boerman,Harry Dolstra,Erik H.J.G. Aarntzen,Willemijn Hobo	30
13	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8⁺ T cells for adoptive immunotherapy 2018 ·OncoImmunology ·(unknown),Willemijn Hobo,Yun Ji,Hanny Fredrix,Valeria De Giorgi,Robert D. Allison,Michel G.D. Kester,J.H. Frederik Falkenburg,Nicolaas Schaap,Joop H. Jansen,Luca Gattinoni,Harry Dolstra,Anniek B. van der Waart	45
14	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer 2018 ·Frontiers in Immunology ·(unknown),(unknown),Elly Marcq,Evelien Smits,Viggo Van Tendeloo,Willemijn Hobo,Eva Lion	75
15	A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma 2017 ·Bone Marrow Transplantation ·(unknown),Mieke W.H. Roeven,Willemijn Hobo,Remco van Doorn,Rimke Oostvogels,J.H. Frederik Falkenburg,Niels W.C.J. van de Donk,Michel G.D. Kester,Hanny Fredrix,Kasper Westinga,Ineke Slaper‐Cortenbach,Eric Spierings,Marie José Kersten,Harry Dolstra,Tuna Mutis,Nicolaas Schaap,H M Lokhorst	23
16	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses 2016 ·The Journal of Immunology ·(unknown),Soley Thordardottir,Hanny Fredrix,(unknown),Rob Woestenenk,Jurjen Tel,Ben Joosten,Alessandra Cambi,Mirjam H.M. Heemskerk,Gerben M. Franssen,Otto C. Boerman,(unknown),Joop H. Jansen,Nicolaas Schaap,Harry Dolstra,Willemijn Hobo	40
17	Ex Vivo Generation of Interstitial and Langerhans Cell-like Dendritic Cell Subset–based Vaccines for Hematological Malignancies 2014 ·Journal of Immunotherapy ·(unknown),Soley Thordardottir,Willemijn Hobo,(unknown),Anniek B. van der Waart,Jeannette Cany,Harry Dolstra,Basav N. Hangalapura	8
18	PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer 2012 ·Journal of Immunotherapy ·John Dulos,Gregory J. Carven,(unknown),(unknown),(unknown),Willemijn Hobo,Monika Górecka,Anton F. J. de Haan,Peter F.A. Mulders,Cornelis J. A. Punt,Joannes F.M. Jacobs,Jack A. Schalken,Egbert Oosterwijk,Hans van Eenennaam,A. Boots	259
19	Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation 2012 ·Cancer Immunology Immunotherapy ·Willemijn Hobo,Tatiana I. Novobrantseva,Hanny Fredrix,Jamie Wong,Stuart Milstein,Hila Epstein-Barash,Ju Liu,Nicolaas Schaap,Robbert van der Voort,Harry Dolstra	113
20	PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation 2011 ·Cancer Research ·Wieger J. Norde,Frans Maas,Willemijn Hobo,Alan J. Korman,Michael Quigley,Michel G.D. Kester,Konnie M. Hebeda,J.H. Frederik Falkenburg,Nicolaas Schaap,Theo M. de Witte,Robbert van der Voort,Harry Dolstra	126

About Willemijn Hobo

Willemijn Hobo is a scholar working on Immunology, Oncology and Hematology, having authored 50 papers that have together received 2.2k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (29 papers), CAR-T cell therapy research (23 papers) and Immunotherapy and Immune Responses (21 papers). The work is most often cited by research in Immunology (1.5k citations), Oncology (1.3k citations) and Hematology (322 citations). Willemijn Hobo has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Harry Dolstra, Nicolaas Schaap, Robbert van der Voort, Frans Maas, Anniek B. van der Waart, Joop H. Jansen, Hanny Fredrix, J.H. Frederik Falkenburg, Wieger J. Norde and Rob Woestenenk. Their work appears in journals such as Nature Communications, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact